Bimal Shah

Direttore/Membro del Consiglio presso ANEBULO PHARMACEUTICALS, INC.

48 anni

Health Technology

Consumer Services

Posizioni attive di Bimal Shah

Società	Posizione	Inizio	Fine
ANEBULO PHARMACEUTICALS, INC.	Direttore/Membro del Consiglio	05/10/2023	-
ANEBULO PHARMACEUTICALS, INC.	Independent Dir/Board Member	05/10/2023	-
Allos Therapeutics, Inc. Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO.	Direttore Finanziario/CFO	05/09/2012	-
	Treasurer	05/09/2012	-

Società	Posizione	Inizio	Fine
SPECTRUM PHARMACEUTICALS, INC.	Corporate Officer/Principal	01/06/2010	01/01/2021

Stanford University

Graduate Degree

Distribuzione geografica

Stati Uniti

Posizioni

Corporate Officer/Principal	1
Director of Finance/CFO	1
Treasurer	1

Settori

Health Technology	4
Consumer Services	2

Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Società quotate in Borsa	2
SPECTRUM PHARMACEUTICALS, INC.	Health Technology
ANEBULO PHARMACEUTICALS, INC.	Health Technology

Aziende private	1
Allos Therapeutics, Inc. Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO.	Health Technology

Aziende private

Health Technology